Celgene (NASDAQ:CELG) Rating Reconfirmed
In analysts note revealed to investors on Friday morning, Celgene (NASDAQ:CELG) stock had its “Buy” Rating maintained by research analysts at Mizuho Securities. They currently have a $158.0 target on company. Mizuho Securities’s target gives a potential upside of 12.42 % from the company’s last stock close.
NASDAQ:CELG is currently trading -0.46% lower at $140.61 as of 10:09 PM New York time. Celgene’s stock is 0% over the last 200 days. It has underperformed the S&P 500, which has risen 6.00% over the same time.
According to data compiled by Thomson Reuters, Celgene (NASDAQ:CELG)’s stock is covered by 22 equity analysts across the Street, with 1 analysts giving it a Sell rating, 20 a Buy rating, while 4 consider it a Hold. The 12-month consensus target price for the stock is $136.82, which reflects an downside potential of 2.70% over the current price.
Oaktop Capital Management Ii L.P. had the most significant stake with ownership of 2.08M shares as of q2 2015 for 50.82% of the fund portfolio. Birchview Capital Lp is another notably bullish investment professional who is possessing 777,051 shares of Celgene or 47.4% of their fund portfolio. Moreover, Selkirk Management Llc have 15.93% of their fund portfolio invested in the company for 248,250 shares. The Switzerland-based fund Bb Biotech Ag disclosed it had purchased so far a stake worth about 12.71% of the investment professional’s stock portfolio in Celgene. The New Jersey-based fund Fcg Advisors Llc is also positive about the stock, possessing 3.46M shares or 11.6% of their fund portfolio.
Celgene (NASDAQ:CELG) Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide).
Celgene (NASDAQ:CELG) traded down -0.46% on 15 September, hitting $140.61. A total of shares of the company’s stock traded hands. This is down from average of 3.24 million shares. Celgene has a 52 week low of $96.93 and a 52 week high of $142.64. The company has a market cap of $110.01 billion and a P/E ratio of 43.73.
Get the latest Celgene (NASDAQ:CELG) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
The post Celgene (NASDAQ:CELG) “Buy” Rating Reiterated by Mizuho Securities; The Target Price is $158.0 appeared first on Octafinance.